A Study to Evaluate the Pharmacokinetics, Efficacy and Safety of Intravenous Golimumab in Pediatric Participants With Active Polyarticular Course Juvenile Idiopathic Arthritis Despite Methotrexate Therapy

This is a single arm, Open-label (all people know the identity of the intervention),
multi-center (when more than one hospital or medical school team work on a medical research
study) study to determine the pharmacokinetics (the study of the way a drug enters and leaves
the blood and tissues over time), efficacy (effectiveness) and safety of intravenous
golimumab in participants with pJIA despite current treatment with methotrexate (MTX). The
study will consist of 3 parts: Screening Phase (6 weeks), an Open-label Treatment Phase
(consists of golimumab and MTX treatment for 244 weeks, wherein after Week 28, MTX dose
change is allowed) and Follow-up Phase (8 weeks). The maximal study duration for a
participant will not exceed 258 weeks. All the eligible participants will be administered
golimumab IV infusion and commercial MTX. Blood samples will be collected for evaluation of
pharmacokinetics of study treatment. Participants' safety will be monitored throughout the
study.

Inclusion Criteria:

- Diagnosis must be made per Juvenile Idiopathic Arthritis (JIA) International League of
Associations for Rheumatology (ILAR) diagnostic criteria and the onset of disease must
have been before the participant's 16th birthday

- Failure or inadequate response to at least a 2 month course of methotrexate (MTX)
before screening

- Participants must have greater than or equal to (>=) 5 joints with active arthritis at
screening and at Week 0 as defined by American College of Rheumatology (ACR) criteria
(that is, a joint with either swelling, or in the absence of swelling, limited range
of motion associated with pain on motion or tenderness)

- Participants must have a screening C-reactive protein (CRP) of >=0.1 milligram
(mg)/deciliter (dL) with the exception of approximately 30 percent (%) of the study
population

- Participants must have active polyarticular juvenile idiopathic arthritis (pJIA)
despite current use of oral, intramuscular, or subcutaneous MTX for >=2 months before
screening. For participants with body surface area (BSA) less than (<)1.67 meter
square (m^2), the MTX dose must be between 10 to 30 milligram per meter square
(mg/m^2) per week and stable for >=4 weeks before screening. For participants with BSA
>=1.67 m^2, the MTX dose must be a minimum of 15 mg/week and must be stable for >=4
weeks before screening. In situations where there is documented intolerance of doses
greater than (>)10 mg/m^2 weekly (for participants with BSA <1.67 m^2) or >=15 mg/week
(for participants with BSA >=1.67 m^2); or where documented country or site
regulations prohibit use of >=15 mg of MTX per week in participants with BSA >=1.67
m^2, participants may be entered into the trial on a lower dose of MTX

Exclusion Criteria:

- Participant has initiated disease-modifying antirheumatic drugs (DMARDs) and/or
immunosuppressive therapy within 4 weeks prior to first study agent administration

- Participant has been treated with intra-articular, intramuscular or intravenous
corticosteroids (including intramuscular corticotropin) during the 4 weeks before
first study agent administration

- Participant has been treated with any therapeutic agent targeted at reducing
Interleukin (IL)-12 or IL 23, including but not limited to ustekinumab and ABT-874,
within 3 months before first study agent administration

- Participant has been treated with natalizumab, efalizumab, or therapeutic agents that
deplete B or T cells (eg, rituximab, alemtuzumab, or visilizumab) during the 12 months
before first study agent administration, or have evidence at screening of persistent
depletion of the targeted lymphocyte after receiving any of these agents

- Participant has been treated with alefacept within 3 months before first study agent
administration

- If a participant has been previously treated with an anti-tumor necrosis factor alpha
(TNF alpha) agent, the reason for discontinuation of the anti-TNF alpha agent cannot
have been a severe or serious adverse event consistent with the class of anti-TNF
alpha agents